{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:21:00Z","timestamp":1791224460808,"version":"4.1.0"},"reference-count":72,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005699","name":"Universit\u00e0 degli Studi del Piemonte Orientale","doi-asserted-by":"publisher","award":["HERMES project"],"award-info":[{"award-number":["HERMES project"]}],"id":[{"id":"10.13039\/501100005699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cisplatin and several non-steroidal anti-inflammatory drugs (NSAIDs) have been proven to act synergistically or at least additively on several tumor cell lines. Dual-action cisplatin-based Pt(IV) combos containing ketoprofen and naproxen offer good antiproliferative performance on a panel of human tumor cell lines, including a malignant pleural mesothelioma (MPM) one, a very chemoresistant tumor. The main reason of the increased activity relies on the enhanced lipophilicity of these Pt(IV) conjugates that in turn promotes increased cellular accumulation. A quick Pt(IV)\u2192Pt(II) reduction generates the active cisplatin metabolite. The NSAID adjuvant action seems to be almost independent from cyclooxygenase-2 (COX-2) expression in the tumor cells under investigation (lung A-549, colon HT-29, HCT 116, SW480, ovarian A2780, and biphasic MPM MSTO-211H), but it seems to rely (at least in part) on the activation of the NSAID activated gene, NAG-1 (a member of the transforming growth factor beta, TGF-\u03b2, superfamily), which has been suggested to be involved in NSAID antiproliferative activity.<\/jats:p>","DOI":"10.3390\/ijms20123074","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:37:40Z","timestamp":1561343860000},"page":"3074","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen \u2020"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-7508","authenticated-orcid":false,"given":"Mauro","family":"Ravera","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2174-508X","authenticated-orcid":false,"given":"Ilaria","family":"Zanellato","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-1955","authenticated-orcid":false,"given":"Elisabetta","family":"Gabano","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Perin","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Rangone","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Coppola","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-9454","authenticated-orcid":false,"given":"Domenico","family":"Osella","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1442-2042.2009.02431.x","article-title":"Recent strategy for the management of advanced testicular cancer","volume":"17","author":"Nakamura","year":"2010","journal-title":"Int. J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1039\/c4dt00911h","article-title":"Pros and cons of bifunctional platinum(IV) antitumor prodrugs: Two are (not always) better than one","volume":"43","author":"Gabano","year":"2014","journal-title":"Dalton Trans."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/ERC-15-0237","article-title":"The state-of-play and future of platinum drugs","volume":"22","author":"Apps","year":"2015","journal-title":"Endoc. Relat. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(IV) anticancer prodrugs\u2014Hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalton Trans."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kenny, R.G., Chuah, S.W., Crawford, A., and Marmion, C.J. (2017). Platinum(IV) Prodrugs\u2014A Step Closer to Ehrlich\u2019s Vision?. Eur. J. Inorg. Chem., 1596\u20131612.","DOI":"10.1002\/ejic.201601278"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jinorgbio.2011.10.012","article-title":"Pt(IV) complexes as prodrugs for cisplatin","volume":"107","author":"Shi","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jinorgbio.2012.06.013","article-title":"What do we know about the reduction of Pt(IV) pro-drugs?","volume":"117","author":"Wexselblatt","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2174\/1381612823666170201161037","article-title":"Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy","volume":"23","author":"Najjar","year":"2017","journal-title":"Curr. Pharm. Design"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinorgbio.2018.11.008","article-title":"Multi-action Pt(IV) anticancer agents; do we understand how they work?","volume":"191","author":"Gibson","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","article-title":"Toward Multi-Targeted Platinum and Ruthenium Drugs\u2014A New Paradigm in Cancer Drug Treatment Regimens?","volume":"119","author":"Kenny","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ica.2019.04.025","article-title":"A view on multi-action Pt(IV) antitumor prodrugs","volume":"492","author":"Ravera","year":"2019","journal-title":"Inorg. Chim. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: Structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2174\/1389557516666160505115743","article-title":"Influencing COX-2 Activity by COX Related Pathways in Inflammation and Cancer","volume":"16","author":"Yu","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-13-1573","article-title":"NSAIDs Inhibit Tumorigenesis, but How?","volume":"20","author":"Gurpinar","year":"2014","journal-title":"Clinical Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2014.01.021","article-title":"Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets","volume":"346","author":"Liggett","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bcp.2005.05.028","article-title":"Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells","volume":"70","author":"Lin","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0223-5234(01)01197-7","article-title":"Cyclooxygenase inhibitors - current status and future prospects","volume":"36","author":"Dannhardt","year":"2001","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: From pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/anie.201308899","article-title":"The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin","volume":"53","author":"Pathak","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1039\/C4CC00419A","article-title":"The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells","volume":"50","author":"Cheng","year":"2014","journal-title":"Chem. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1039\/C6MT00066E","article-title":"Asplatin enhances drug efficacy by altering the cellular response","volume":"8","author":"Cheng","year":"2016","journal-title":"Metallomics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cmdc.201402074","article-title":"Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance","volume":"9","author":"Neumann","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/cmdc.201402353","article-title":"Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance","volume":"10","author":"Neumann","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ica.2017.07.019","article-title":"Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug","volume":"472","author":"Curci","year":"2018","journal-title":"Inorg. Chim. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acs.molpharmaceut.8b00070","article-title":"A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity","volume":"15","author":"Tan","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.bmc.2017.03.007","article-title":"Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents","volume":"25","author":"Qin","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bcp.2017.03.004","article-title":"Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-kappa B pathways","volume":"135","author":"Chen","year":"2017","journal-title":"Biochem.Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejmech.2018.01.001","article-title":"Biotin conjugated organic molecules and proteins for cancer therapy: A review","volume":"145","author":"Maiti","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jinorgbio.2017.07.002","article-title":"Biotin-Pt(IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance","volume":"175","author":"Hu","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tolan, D.A., Abdel-Monem, Y.K., and El-Nagar, M.A. (2019). Anti-tumor platinum(IV) complexes bearing the anti-inflammatory drug naproxen in the axial position. Appl. Organ. Chem., e4763.","DOI":"10.1002\/aoc.4763"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs","volume":"104","author":"Cryer","year":"1998","journal-title":"Am. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1021\/cr4004314","article-title":"Synthetic Methods for the Preparation of Platinum Anticancer Complexes","volume":"114","author":"Wilson","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1039\/C5DT04905A","article-title":"Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido\/carboxylato prodrugs","volume":"45","author":"Ravera","year":"2016","journal-title":"Dalton Trans."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ica.2015.07.042","article-title":"Application of microwave-assisted heating to the synthesis of Pt(II) complexes","volume":"437","author":"Gabano","year":"2015","journal-title":"Inorg. Chim. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1039\/C4DT03617D","article-title":"Microwave-assisted synthesis of the anticancer drug cisplatin, cis-Pt(NH3)2Cl2","volume":"44","author":"Petruzzella","year":"2015","journal-title":"Dalton Trans."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1039\/C7DT04614F","article-title":"The cisplatin-based Pt(IV)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions","volume":"47","author":"Gabano","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1039\/C8DT03950J","article-title":"Synthesis and characterization of cyclohexane-1R,2R-diamine-based Pt(IV) dicarboxylato anticancer prodrugs: Their selective activity against human colon cancer cell lines","volume":"48","author":"Gabano","year":"2019","journal-title":"Dalton Trans."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity and Its Relationship with Passive Drug Permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/hlca.200890164","article-title":"Retention behavior of neutral and positively and negatively charged solutes on an immobilized-artificial-membrane (IAM) stationary phase","volume":"91","author":"Lin","year":"2008","journal-title":"Helvet. Chim. Acta"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1021\/jm070740j","article-title":"Reduction of cis,trans,cis-PtCl2(OCOCH3)2(NH3)2 by aqueous extracts of cancer cells","volume":"50","author":"Nemirovski","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14174","DOI":"10.1039\/C7DT02928D","article-title":"An unsymmetric cisplatin-based Pt(IV) derivative containing 2-(2-propynyl) octanoate: A very efficient multi-action antitumor prodrug candidate","volume":"46","author":"Gabano","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.ccr.2008.01.016","article-title":"Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry","volume":"252","author":"Ronconi","year":"2008","journal-title":"Coord. Chem. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1021\/ic8006734","article-title":"1H, 15N heteronuclear single quantum coherence NMR study of the mechanism of aquation of platinum(IV) ammine complexes","volume":"47","author":"Davies","year":"2008","journal-title":"Inorg. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ijc.11710","article-title":"Reclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention","volume":"109","author":"Catalano","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394C method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/nprot.2006.236","article-title":"Quantification of mRNA using real-time RT-PCR","volume":"1","author":"Nolan","year":"2006","journal-title":"Nat. Protocols"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-2952(96)00106-2","article-title":"Cellular distribution and cellular reactivity of platinum(II) complexes","volume":"52","author":"Lindauer","year":"1996","journal-title":"Biochem. Pharmacol.y"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2013.09.003","article-title":"Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells","volume":"129","author":"Alessio","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1124\/mol.104.005108","article-title":"Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein","volume":"67","author":"Baek","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1124\/mol.59.4.901","article-title":"Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities","volume":"59","author":"Baek","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/106689690301100302","article-title":"Overexpression of NSAID-activated gene product in prostate cancer","volume":"11","author":"Iczkowski","year":"2003","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2009.03.006","article-title":"A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2","volume":"282","author":"Iguchi","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1124\/jpet.301.3.1126","article-title":"Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene","volume":"301","author":"Baek","year":"2002","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ijc.11173","article-title":"Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells","volume":"105","author":"Wilson","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_65","first-page":"649","article-title":"NSAID activated gene (NAG-1), a modulator of tumorigenesis","volume":"39","author":"Eling","year":"2006","journal-title":"J. Biochem. Mol. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"C166","DOI":"10.1152\/ajpcell.2001.281.1.C166","article-title":"Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells","volume":"281","author":"Parfenova","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"C184","DOI":"10.1152\/ajpcell.00346.2006","article-title":"Differential subcellular localization of COX-2 in macrophages phagocytosing heat-killed Mycobacterium bovis BCG","volume":"293","author":"Yamashita","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jinorgbio.2016.11.024","article-title":"May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs?","volume":"167","author":"Ravera","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1039\/C2DT32360E","article-title":"Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(iv) complexes","volume":"42","author":"Ermondi","year":"2013","journal-title":"Dalton Trans."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00775-010-0731-1","article-title":"Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes","volume":"16","author":"Platts","year":"2011","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ica.2015.03.039","article-title":"Host-guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrins","volume":"432","author":"Ravera","year":"2015","journal-title":"Inorg. Chim. Acta"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2015.05.012","article-title":"Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs","volume":"150","author":"Ravera","year":"2015","journal-title":"J. Inorg. Biochem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:00:44Z","timestamp":1760187644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20123074"],"URL":"https:\/\/doi.org\/10.3390\/ijms20123074","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]}}}